Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma

Peking University First Hospital3,677 enrolled

Overview

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are: What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. This cohort study aims to identify prognostic factors, construct predictive nomograms, and optimize surgical treatment for sporadic BRCC patients. The main questions it aims to answer are: What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? In this retrospective population-based cohort study, patients diagnosed with sporadic BRCC between 2000 and 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.

Study Type

OBSERVATIONAL

Enrollment

3,677

Conditions

Kidney Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years. * Clinical diagnosis of localized BRCC (M0) from 2000 to 2020. * Active follow-up. * Complete clinicopathological information. Exclusion Criteria: * Diagnosed by autopsy or death certificate only. * Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma. * Unavailable key information.

Outcomes

Primary Outcomes

Overall survival (OS)

OS was calculated as the time interval from the diagnosis of the second primary RCC to death or the time to the last follow-up.

Time frame: From date of diagnosis of the second primary RCC until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 20 years.

Secondary Outcomes

Cancer-specific survival (CSS)

CSS was calculated as the time interval from the diagnosis of the second primary RCC to death from the same disease or the last follow-up.

Time frame: From date of diagnosis of the second primary RCC until the date of death from the same disease or the date of last follow-up, whichever came first, assessed up to 20 years.